List view / Grid view
15 December 2015 | By Victoria White
The proposed transaction would consist of an exchange of Sanofi animal health business (Merial) and Boehringer Ingelheim consumer healthcare (CHC) business...
6 November 2015 | By Victoria White
Sotagliflozin is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 which could be a potential treatment option for people with diabetes...
5 November 2015 | By Victoria White
Sanofi and Hanmi have entered a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments...
29 September 2015 | By Victoria White
The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study...
28 September 2015 | By Victoria White
Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy...
14 September 2015 | By Victoria White
The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c compared with insulin glargine alone...
26 August 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Praluent (alirocumab) Injection - the first and only PCSK9 inhibitor approved in the US...
4 August 2015 | By Victoria White
Toujeo is now available in the UK, providing another option for adults with type 1 and type 2 diabetes mellitus to help manage their condition...
29 July 2015 | By Victoria White
Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin...
15 July 2015 | By Victoria White
Sanofi plans to evolve its business with the creation of five Global Business Units: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.
8 July 2015 | By Victoria White
Sanofi is to extend its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new single, fixed-dose combination therapy for malaria...
9 June 2015 | By Victoria White
Results of the ELIXA study assessing the cardiovascular safety of lixisenatide in adults with type 2 diabetes and high CV risk have been presented...
8 June 2015 | By Victoria White
Sanofi has announced results from two extension studies where participants with diabetes received Toujeo or Lantus treatment for a total of 12 months...
1 June 2015 | By Victoria White
A new study compared the effectiveness of cabazitaxel alone versus cabazitaxel combined with carboplatin in patients with mCRPC...
21 May 2015 | By Victoria White
Phase 3 study of sarilumab met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis...
